{"patent_id": "10-2017-0144930", "section": "특허_기본정보", "subsection": "특허정보", "content": {"공개번호": "10-2019-0049275", "출원번호": "10-2017-0144930", "발명의 명칭": "PET기반의 파킨슨병 원인 질환 판별방법 및 프로그램", "출원인": "재단법인 아산사회복지재단", "발명자": "김재승"}}
{"patent_id": "10-2017-0144930", "section": "청구범위", "subsection": "청구항", "claim_number": "청구항_1", "content": "PET기반의 파킨슨병 원인 질환 판별방법."}
{"patent_id": "10-2017-0144930", "section": "청구범위", "subsection": "청구항", "claim_number": "청구항_2", "content": "하드웨어인 컴퓨터와 결합되어, PET기반의 파킨슨병 원인 질환 판별방법을 수행할 수 있도록 컴퓨터에서 독출가능한 기록매체에 저장된 컴퓨터프로그램."}
{"patent_id": "10-2017-0144930", "section": "발명의_설명", "subsection": "요약", "paragraph": 1, "content": "PET를 이용한 질환분석 방법."}
{"patent_id": "10-2017-0144930", "section": "발명의_설명", "subsection": "기술분야", "paragraph": 1, "content": "본 발명은 PET를 이용한 질환분석 방법에 관한 것이다."}
{"patent_id": "10-2017-0144930", "section": "발명의_설명", "subsection": "배경기술", "paragraph": 1, "content": "PET는 Positron Emission Tomography의 약자로, 양전자를 방출하는 방사성 의약품을 이용하여 인체에 대한 생리 화학적, 기능적 영상을 3차원으로 얻는 핵의학 영상법을 말한다. 본 발명이 해결하고자 하는 과제는 PET를 이용한 질환분석 방법을 제공하는 것이다. 본 발명이 해결하고자 하는 과제들은 이상에서 언급된 과제로 제한되지 않으며, 언급되지 않은 또 다른 과제들 은 아래의 기재로부터 통상의 기술자에게 명확하게 이해될 수 있을 것이다."}
{"patent_id": "10-2017-0144930", "section": "발명의_설명", "subsection": "발명을실시하기위한구체적인내용", "paragraph": 1, "content": "본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 첨부되는 도면과 함께 상세하게 후술되어 있는 실시 예들을 참조하면 명확해질 것이다. 그러나, 본 발명은 이하에서 개시되는 실시예들에 제한되는 것이 아니라 서 로 다른 다양한 형태로 구현될 수 있으며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술 분야의 통상의 기술자에게 본 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다. 본 명세서에서 사용된 용어는 실시예들을 설명하기 위한 것이며 본 발명을 제한하고자 하는 것은 아니다. 본 명 세서에서, 단수형은 문구에서 특별히 언급하지 않는 한 복수형도 포함한다. 명세서에서 사용되는 \"포함한다 (comprises)\" 및/또는 \"포함하는(comprising)\"은 언급된 구성요소 외에 하나 이상의 다른 구성요소의 존재 또는 추가를 배제하지 않는다. 명세서 전체에 걸쳐 동일한 도면 부호는 동일한 구성 요소를 지칭하며, \"및/또는\"은 언급된 구성요소들의 각각 및 하나 이상의 모든 조합을 포함한다. 비록 \"제1\", \"제2\" 등이 다양한 구성요소들을 서술하기 위해서 사용되나, 이들 구성요소들은 이들 용어에 의해 제한되지 않음은 물론이다. 이들 용어들은 단 지 하나의 구성요소를 다른 구성요소와 구별하기 위하여 사용하는 것이다. 따라서, 이하에서 언급되는 제1 구성 요소는 본 발명의 기술적 사상 내에서 제2 구성요소일 수도 있음은 물론이다. 다른 정의가 없다면, 본 명세서에서 사용되는 모든 용어(기술 및 과학적 용어를 포함)는 본 발명이 속하는 기술 분야의 통상의 기술자에게 공통적으로 이해될 수 있는 의미로 사용될 수 있을 것이다. 또한, 일반적으로 사용되 는 사전에 정의되어 있는 용어들은 명백하게 특별히 정의되어 있지 않는 한 이상적으로 또는 과도하게 해석되지 않는다.명세서에서 사용되는 \"부\" 또는 “모듈”이라는 용어는 소프트웨어, FPGA 또는 ASIC과 같은 하드웨어 구성요소 를 의미하며, \"부\" 또는 “모듈”은 어떤 역할들을 수행한다. 그렇지만 \"부\" 또는 “모듈”은 소프트웨어 또는 하드웨어에 한정되는 의미는 아니다. \"부\" 또는 “모듈”은 어드레싱할 수 있는 저장 매체에 있도록 구성될 수 도 있고 하나 또는 그 이상의 프로세서들을 재생시키도록 구성될 수도 있다. 따라서, 일 예로서 \"부\" 또는 “모 듈”은 소프트웨어 구성요소들, 객체지향 소프트웨어 구성요소들, 클래스 구성요소들 및 태스크 구성요소들과 같은 구성요소들과, 프로세스들, 함수들, 속성들, 프로시저들, 서브루틴들, 프로그램 코드의 세그먼트들, 드라 이버들, 펌웨어, 마이크로 코드, 회로, 데이터, 데이터베이스, 데이터 구조들, 테이블들, 어레이들 및 변수들을 포함한다. 구성요소들과 \"부\" 또는 “모듈”들 안에서 제공되는 기능은 더 작은 수의 구성요소들 및 \"부\" 또는 “모듈”들로 결합되거나 추가적인 구성요소들과 \"부\" 또는 “모듈”들로 더 분리될 수 있다. 공간적으로 상대적인 용어인 \"아래(below)\", \"아래(beneath)\", \"하부(lower)\", \"위(above)\", \"상부(upper)\" 등 은 도면에 도시되어 있는 바와 같이 하나의 구성요소와 다른 구성요소들과의 상관관계를 용이하게 기술하기 위 해 사용될 수 있다. 공간적으로 상대적인 용어는 도면에 도시되어 있는 방향에 더하여 사용시 또는 동작시 구성 요소들의 서로 다른 방향을 포함하는 용어로 이해되어야 한다. 예를 들어, 도면에 도시되어 있는 구성요소를 뒤 집을 경우, 다른 구성요소의 \"아래(below)\"또는 \"아래(beneath)\"로 기술된 구성요소는 다른 구성요소의 \"위 (above)\"에 놓여질 수 있다. 따라서, 예시적인 용어인 \"아래\"는 아래와 위의 방향을 모두 포함할 수 있다. 구성 요소는 다른 방향으로도 배향될 수 있으며, 이에 따라 공간적으로 상대적인 용어들은 배향에 따라 해석될 수 있 다. 이하, 첨부된 도면을 참조하여 본 발명의 실시예를 상세하게 설명한다. 본 명세서에서는, PET 영상과 인공지능 기술을 이용하여 질병을 분류 및 추정하는 방법이 개시된다. 인공지능 기술은 머신러닝(Machine Learning, 기계학습) 기술을 포함하며, 머신러닝 기술 중에서도 특히 영상을 분석하는 데 널리 이용되는 딥러닝(Deep Learning) 기술을 포함한다. 딥 러닝은 여러 비선형 변환기법의 조합을 통해 높은 수준의 추상화(abstractions, 다량의 데이터나 복잡한 자"}
{"patent_id": "10-2017-0144930", "section": "발명의_설명", "subsection": "발명을실시하기위한구체적인내용", "paragraph": 2, "content": "료들 속에서 핵심적인 내용 또는 기능을 요약하는 작업)를 시도하는 기계학습(machine learning) 알고리즘의 집 합으로 정의된다. 딥 러닝은 큰 틀에서 사람의 사고방식을 컴퓨터에게 가르치는 기계학습의 한 분야로 볼 수 있 다. 특히, 개시된 실시 예에 따른 분석방법은 파킨슨 병 또는 파킨슨 병과 유사한 증상을 갖는 질환들을 분류하는 데 이용된다. 파킨슨병은 도파민이 부족해져서 발생하는 것으로 추정되는 병으로, 도파민제제를 복용하면 증상이 일시적으로 호전될 수는 있으나, 파킨슨병 자체가 완치되지는 않는다. 오히려 시간이 지남에 다라 약효가 줄어들고, 이상운 동 등의 부작용이 나타나는 경우도 많다. 한편, 파킨슨병과 유사한 질환으로 MSA(다발성 신경계 위축), PSP(진행성 핵상마비), CBD(피질기저핵 변성), NPH(정상압 수두증), vascular parkinsonism(중풍 후 파킨슨) 등이 있는데, 이러한 질환들은 파킨슨약에 대한 반응이 없을 뿐만 아니라, 오히려 부작용이 발생할 수도 있다. 따라서, 파킨슨 병 또는 파킨슨 병과 유사한 질환을 가진 환자에 대하여 PET 검사를 통해 환자가 보유한 질환을 정확히 판단하고자 하나, 단순히 PET 영상만으로는 환자가 보유한 질환을 판단하기 어려운 경우가 있다. 따라서, 이하에서는 PET 중에서도 18F-FDG PET와, 18F-FPCIT PET 영상, 더 구체적으로는 18F-FDG PET 영상, Early phase 18F-FPCIT PET 영상 및 Delay phase 18F-FPCIT PET 영상 중 하나 이상을 이용하여 PD(Parkinson’s disease, 파킨슨 병), MSA(Multiple system atrophy, 다발성 신경계 위축) 및 PSP(Progressive supranuclear palsy, 진행성 핵상마비)를 구분하는 방법에 대하여 설명한다. 18F-FDG PET 영상과 18F-FPCIT PET 영상만으로는 PD, MSA 및 PSP를 구분하기 어렵다. 따라서, 개시된 실시 예에 따르면 18F-FDG PET 영상, Early phase 18F-FPCIT PET 영상 및 Delay phase 18F-FPCIT PET 영상 중 하나 이상을 이용하여 머신러닝을 수행함으로써 학습된 모델을 획득하고, 학습된 모델을 이용하여 적어도 하나의 PET 영상으 로부터 PD, MSA 및 PSP를 구분한다. 개시된 실시 예에 따르면 선형 판별분석(Linear Discriminant Analysis, LDA) 및 Support vector machine (SVM) 을 이용하여 PET 영상을 이용한 학습을 수행하고, 학습된 모델을 획득한다. 예를 들어, 18F-FDG PET 영상을 이용하여 머신러닝을 수행하거나, Delay phase 18F-FPCIT PET 영상을 이용하여 머신러닝을 수행할 수 있다. 다른 예로, 18F-FDG PET 영상과 Delay phase 18F-FPCIT PET 영상을 이용하여 머신러닝을 수행하는 경우, 더 높은 정확도로 질환을 구별할 수 있는 모델을 획득할 수 있다. 하지만, 이 경우 PET 촬영을 두 번 해야 하는 번거로 움이 있다. 따라서, 바람직하게는 단일 영상을 이용하는 것보다 높은 정확도를 가지며, 한 번의 PET 촬영만으로도 획득할 수 있는 Early phase 18F-FPCIT PET 영상 및 Delay phase 18F-FPCIT PET 영상을 이용하여 머신러닝을 수행, 환자 의 질환을 구분할 수 있는 모델을 획득할 수 있다. 이를 Dual Phase 18F-FPCIT PET 영상을 이용한 학습방법이라 한다. 일 실시 예에서, PET 영상을 이용하여 머신러닝을 수행하는 경우, 각 PET 영상을 복수 개의 영역으로 구분하여, 구분된 각 영역이 방사성 약품에 반응(섭취)하는 정도에 기초하여 학습 데이터를 생성하고, 학습시킴으로써, 각 PET 영상에 대응하는 질환을 구분할 수 있는 모델을 획득할 수 있다. 예를 들어, 영역별 섭취량(섭취도)의 비율 에 기초하여 학습을 수행할 수 있다. 마찬가지로, PET 영상을 이용하여 머신러닝을 수행하는 경우, 서로 다른 종류의 PET 영상으로부터 복수 개의 특 징을 추출, 추출된 특징들을 이용하여 학습 데이터를 생성하고, 학습시킴으로써, 각 PET 영상에 대응하는 질환 을 구분할 수 있는 모델을 획득할 수 있다. 예를 들어, Delay phase 18F-FPCIT PET 영상으로부터 특징을 추출하는 방법에 대해서는 도 1에 개시된 설명에 따른다. 예를 들어, Delay phase 18F-FPCIT PET 영상을 이용하여 머신러닝을 수행하는 경우, 7개의 특징을 추출하고, PD, PSP 및 MSA가 라벨링된 학습 데이터를 이용하여 학습을 수행한다. 또한, Early phase 18F-FPCIT PET 영상 및 18F-FDG PET 영상으로부터 특징을 추출하는 방법에 대해서는 도 2에 개시된 설명에 따른다. 예를 들어, 18F-FDG PET 영상을 이용하여 머신러닝을 수행하는 경우, 6개의 특징을 추출하고, PD, PSP 및 MSA가 라벨링된 학습 데이터를 이용하여 학습을 수행한다. 다른 예로, 18F-FDG PET 영상과 Delay phase 18F-FPCIT PET 영상을 이용하여 머신러닝을 수행하는 경우, 13개의 특징을 추출하고, PD, PSP 및 MSA가 라벨링된 학습 데이터를 이용하여 학습을 수행한다. 또 다른 예로, Early phase 18F-FPCIT PET 영상 및 Delay phase 18F-FPCIT PET 영상을 이용하여 머신러닝을 수행 하는 경우, 13개의 특징을 추출하고, PD, PSP 및 MSA가 라벨링된 학습 데이터를 이용하여 학습을 수행한다. 결과적으로, Dual Phase 18F-FPCIT PET 영상을 이용하여 머신러닝을 수행, PD, PSP 및 MSA를 구분할 수 있는 학 습된 모델을 획득할 수 있다. 일 실시 예에서, Early phase 18F-FPCIT PET 영상 및 Delay phase 18F-FPCIT PET 영상을 비교함으로써 PD, PSP 및 MSA를 구분할 수 있다. 예를 들어, Early phase 18F-FPCIT PET 영상 및 Delay phase 18F-FPCIT PET 영상을 비교하고, 비교 결과에 기초 하여 머신러닝을 수행, PD, PSP 및 MSA를 구분할 수 있는 모델을 획득할 수 있다. 상술한 PD, PSP 및 MSA는 예시로서 제공된 것이고, 다른 질환들 또한 개시된 실시 예에 따라 분류가능하게 학습 되고, 분류될 수 있다. 이하에서는 개시된 실시 예와 관련된 내용을 첨부한다. Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. Purpose: Regional cerebral perfusion is coupled to metabolism in general. Early perfusion dominant imaging using 18F-FP-CIT PET (pCIT) may provide complementary information to delayed dopamine transporter dominant images. We investigated the ability of pCIT to differentiate atypical Parkinson disorder from Parkinson disease (PD) compared to FDG and the image quality for optimizing the acquisition time. Methods: Sixty-seven subjects [PD, 23 subjects; multiple system atrophycerebellar type (MSA-C), 27 subjects; MSA-Parkinson type (MSA-P), 12 subjects; and progressive supranuclear palsy (PSP), 5 subjects] underwent 18F-FP-CIT and FDG PET. Using dynamic PET data acquired during the first 10minutes after 18F-FP-CITadministration,we generated potential perfusion images of 0 to 5 (pCIT-5m), 0 to 7 (pCIT-7m), and 0 to 10 (pCIT-10m) minutes. We compared regional uptake between groups in pCIT and FDG images and image quality among pCIT images using visual, quantitative, or statistical parametric mapping analyses. Results: Regional cerebral uptake of pCITs correlated well to that of the FDG images (R > 0.5, all). Multiple system atrophy-cerebellar type and MSA-P groups show different regional uptake patterns compared with PD group on pCITs in quantitative and statistical parametric mapping analyses, analogous to FDG images, but not in the PSP group. In visual analysis, concordance rates between each pCIT and FDG image were high (92.3%?96.0%, regional; 86.2%?93.1%, diagnostic), and there was no significant difference among pCITs. However, pCIT-10m discriminated PSP better than others and showed higher signal-to-noise ratio (P = 0.001). Conclusion: 18F-FP-CIT PETs with the first 10 minutes could be useful for the differential diagnosis of atypical Parkinson disorder by providing complementary FDG-like information to the dopamine transporter binding on late-phase FP-CIT images. Key Words: early phase, PET, 18F-FP-CIT, 18F-FDG, parkinsonism. Parkinsonism is a neurological syndrome characterized by tremor, bradykinesia, rigidity, and postural instability.1 Idiopathic Parkinson disease (PD) is the most common neurodegenerative cause of parkinsonism2 followed by atypical Parkinson disorders (APDs), such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP).3 Atypical Parkinson disorders are often difficult to differentiate from PD based on the clinical findings, particularly in the early stage, because of the similarity of phenotypes and lack of diagnostic markers.4,5 Accurate differential diagnosis of APD from PD is important for deciding on treatment regimens,6 providing a prognosis,7 clarifying etiology and pathogenesis, and developing new therapeutic strategies.8 Definite diagnosis of parkinsonism requires a neuropathological examination, which can be impractical. Functional brain imaging techniques have been increasingly used in the differential diagnosis of parkinsonism. Typically, imaging of the availability of presynaptic dopamine transporters (DAT) is very sensitive in detecting neurodegenerative parkinsonian disorders, PD, and APD. However, DAT imaging is poor at discriminating them.9,10 In contrast, assessment of regional cerebral glucose metabolism using 18F-FDG PET can be helpful and is widely used for differential diagnosis of parkinsonian disorders.11?13 In typical PD, glucose metabolism of lentiform nucleus is preserved or raised, whereas it is reduced in most APDs.14?16 The accurate diagnosis of PD and APDs often requires both 18F-FDG PET and DAT imaging. This can be inconvenient for the patient and increases radiation exposure, and adds to health care costs. N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane (18F-FP-CIT) is a PET tracer for DAT imaging. Its pharmacokinetics have been well established.17?20 Uptake of 18F-FP-CIT rapidly increases with time in the brain cortex and striatum, with a high first-pass influx rate (K1) evident in the first 15 minutes.17 These early high-value K1 images in 18F-FP-CIT PET (pCIT) can contain information related to K1,21 which is indicative of regional cerebral blood flow22 that is generally coupled to cerebral metabolism.23 We would therefore anticipate a correlation between perfusion dominant data from early images obtained using pCIT and metabolic data from 18F-FDG. Such a potential has been chronicled previously,24 although time-related limitationswere present. The human brain harbors several dopamine-rich regions including the striatum and midbrain, and many dopamine-poor regions including the cerebral and cerebellar cortex. These regions display marked differences in the pharmacokinetics of 18F-FPCIT. 17?20 Therefore, it is important to optimize the acquisition time of pCIT showing perfusion dominant pattern withminimal dopaminergic effect in all of the brain regions without significant loss of image quality. This study was undertaken to assess the clinical feasibility of pCIT. We investigated the ability of pCIT to separate APDs from PD like FDG with regard to regional uptake pattern and compared the image quality among pCITs for optimizing the acquisition time. PATIENTS AND METHODS Subjects Since August 2013, we performed dual-phase pCIT dynamic imaging with the first 10 minutes and 3-hour delayed images in patients suspected of APD or PD. Subjects with a diagnosis of PD, MSA, or PSP who underwent static FDG brain PET less than 1 year before or after dual-phase pCITwere included. The diagnosis of PD was based on UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.25 Patients with clinically probable PSP (classic Richardson syndrome), MSA-parkinsonian type (MSA-P), and MSA-cerebellar type (MSA-C) were enrolled based on current diagnostic criteria.26,27 All patients were assessed by a neurologist specializing in movement disorders. Their medical records were available. The severity of parkinsonian symptoms was evaluated with modified Hoehn-Yahr stage. Structural magnetic resonance imaging (MRI) was also assessed to evaluate other neurological diseases, especially brain infarction. This study was approved by the Institutional Review Board of our institution. Radiopharmaceutical Synthesis 18F-FP-CITwas synthesized with a protic solvent (t-butanol or t-amyl alcohol) as a reaction solvent and N-[3′-(tosyloxy) propyl]-2β-carbomethoxy-3β-(4′iodophenyl)nortropane as a precursor.28 Radiochemical purity exceeded 98% after purification by high-performance liquid chromatography, and the specific activity was 445.8 ± 240.5 GBq/μmol at the end of synthesis. Data Acquisition 18F-FP-CIT PET was performed using a Biograph 40 TruePoint PET/CT camera (Siemens Medical Systems, USA) with an in-plane spatial resolution of approximately 2.0-mmfull width at half maximum (FWHM) at the center of the field of view by virtue of the point spread function-based iterative reconstruction algorithm. After intravenous injection of 18F-FP-CIT (185 MBq), PET scan was acquired for the first 10 minutes after injection with a list mode. Routine delay image acquisition was started 3 hours after injection. Emission PET data were acquired in the 3-dimensional (3D) mode after brain CT, which was performed in the spiral mode at 120 kV(peak) and 380mA s (reference standard) with the CARE Dose 4D program. [18F]FP-CIT PET images were reconstructed from CT data for attenuation correction by use of the TrueX algorithm (6 iterations, 16 subsets; zoom: 2) and an all-pass filter with a 336, 336 matrix. 18F-FDG PET was also performed after patients had fasted for at least 6 hours before the scan. A 15-minute scan was done 40 minutes after intravenous injection of 18F-FDG (370 MBq). 18F-FDG PET was performed using a Discovery PET/CT 690 apparatus (General Electric Healthcare, UK), which provided an in-plane spatial resolution of approximately 4.7 mm FWHM. FDG PET images were reconstructed using a 3D ordered subset expectation maximization algorithm (3 iterations, 16 subsets; zoom: 2) and 2-mm Gaussian filter. Image Processing All image datawere processed and analyzed using the SPM2 (Wellcome Department of Imaging Neuroscience, Institute of Neurology, University College London) equipped with MATLAB 2012a software (The MathWorks, Inc). Using PET data acquired during the first 10 minutes with a listmode, we iteratively generated pCIT images of 0 to 5 (pCIT-5m), 0 to 7 (pCIT-7m), and 0 to 10 (pCIT-10m) minutes. Then, the data from a Digital Imaging and Communications in Medicine file were converted into an analysis format usingMRIcro version 1.37 (MRIro, USA). The pCITs from each subject were coregistered to an individual FDG image. FDG images were spatially normalized into the FDG template, and their transformation matrixes were applied to spatial normalization of pCITs. The spatially normalized PET images were smoothed by an isotropic Gaussian Kernelwith 12-mm FWHMto accommodate interindividual anatomic variability and to improve the signal-tonoise ratio and normality (ie, Gaussianity) of the image signal for statistical parametric mapping (SPM) analysis. Analyses of Group Differences in pCITs and FDG Images Visual Analysis After randomization of FDG and pCIT images, respectively, 3 nuclear medicine physicians blinded to the clinical information and the time frame of pCITs interpreted all FDG and pCIT images. They categorized the regional uptake of representative regions defined as most characteristic region in each APD differentiating with PD, putamen in MSA-P, cerebellum in MSA-C, and frontal cortex and midbrain in PSP using a 3-point scale. The images were then classified as PD,MSA-P,MSA-C, or PSP based on previous criteria of their glucose metabolism or brain perfusion; decreased regional uptake of the putamen, pons, and cerebellum in MSA-P; decreased regional uptake of the cerebellum in MSA-C; decreased regional uptake of the caudate nucleus, thalamus, midbrain, medial frontal cortex, and cingulate gyrus in PSP.11,29,30 The regional and diagnostic interobserver agreements were measured. Quantitative Analysis The quantitative regional uptake values for the spatially normalized pCIT and FDG images were obtained using predefined volumes of interest (VOIs). The bilateral superior frontal gyri, putamen, and whole cerebralVOIs in an anatomical labeling template,31 midbrain drawnmanually on coregistered, spatially normalized, single T1-weightedMRI and pCIT template images by an experienced nuclear medicine physician specializing in nuclear neurology, and the cerebellummade fromcerebellarVOI in an in-house anatomical labeling template with 2-pixel erosion for the best spatial normalization results in a Korean population were used. The activity concentration in each VOI was calculated. The uptake ratio (UR) was defined as activity of each VOI divided by mean activity of whole cerebral VOIs. Values were compared by disease group, PD as a reference and modality, and FDG as a reference. Regional correlation coefficients (R) were also calculated between each pCIT image and the corresponding FDG image within subject. SPM Analysis Statistical parametric mapping analysis was performed to assess group differences in PD versus MSA-P, MSA-C, or PSP. Only regions that exceeded a threshold of uncorrected P < 0.01 were accepted as significant. Comparison of Image Quality Among pCITs In visual analysis, noisewas categorized using a 3-point scale and compared among pCITs. In quantitative analysis, the coefficient of variation (CV; standard deviation of uptake ÷ mean uptake) of each pCITwas calculated as a reciprocal value of the signal-tonoise ratio (SNR). We used a simple and fast algorithm for image noise estimation,32 where the input image is assumed to be corrupted by additive zero mean Gaussian noise. To exclude structures or details from contributing to the noise variance estimation, an edge detection algorithm was first applied and noise variance was estimated using a combination of 2 Laplacian operators. The mean noise variance was estimated on each axial slice, and the maximum value was picked as the representative value in each individual pCIT. Specifically, we removed background anatomical information of the PET image using a combined kernel of 2 Laplacian operators.32 For comparison of contrast, gray matter (GM) and white matter (WM) were delineated using a priori information of WM segmentation in SPM. In this way, GM/WM ratios of frontal lobe and putamen for each pCITwere obtained using the template mentioned previously. Statistical Analyses Quantitative variables are reported as mean ± standard deviation. Correlations each pCITs and FDGimagewere analyzed using Pearson correlation analysis. Uptake ratio between each APD and PD was compared using independent t test. Differences of UR, SNR, and contrast with time frames of pCITs were analyzed using multivariate analysis of variance. SPSS for Windows version 12 (SPSS Inc, USA) was used for statistical analyses. P < 0.05 was considered statistically significant. RESULTS Clinical Characteristics of Subjects Seventy-six subjects with a diagnosis of PD, MSA-P, MSAC, or PSP who had undergone both dual-phase pCITand FDG brain PET were included. Five subjects with different findings between FDG PETand clinical diagnosis and 4 subjectswith a suspicious diagnosis combined with another neurodegenerative disease were excluded. Finally, 67 subjects were analyzed (PD, 23; MSA-P, 12; MSA-C, 27; and PSP, 5). The clinical characteristics of the subjects are summarized in Table 1. There were no significant differences in age, sex, and modified Hoehn-Yahr stage among the disease groups. However, PD patients had longer disease duration than patients in theMSA-P, MSA-C, and PSP groups. It is becausemany of the patients with PD (15/23) underwent 18F-FP-CIT and 18F-FDG PET for workup before deep-brain stimulation, in contrast with patients with APD, for diagnostic workup. PET/CT and structural MRI in all patients revealed the absence of significant cortical or subcortical infarction. Group Differences in FDG and pCIT Images Visual Analysis Representative images of FDG and pCITs PET in each group are shown in Figure 1. The regional distribution pattern in the each pCIT was similar to that of the FDG for all groups in most areas. It was not difficult to detect the decrease of representative regional uptake, especially putamen in MSA-P and cerebellum in MSA-C. In pCITs, however, it was difficult to detect the decrease of midbrain uptake in PSP. Concordance rates of regional uptake between each pCIT and FDG image were high (92.3%?96.0%, regional; 86.2?93.1%, diagnostic), and there was no significant difference among 3 pCITs with good diagnostic interobserver agreement of the 3 interpreters (Fleiss κ coefficient, 0.868; P < 0.05). For PSP, the concordance rate between each pCIT and FDG image was low (40%, 2/5) except pCIT-10m images (80%, 4/5). Quantitative Analysis Uptake ratios of representative regions of each APD compared with PD are shown in Figure 2. In MSA-P and MSA-C, URs of putamen and cerebellum were significantly lower than those of PD in FDG and all pCITs, respectively. Notably, all cerebellar URs of PD were more than 1.0 and those of MSA-C subjects were less than 1.0 in all pCITs, but not in FDG images, showing decreased cerebellar uptake than cerebral uptake even in the PD group. In PSP, URs of superior frontal VOI were significantly lower than those of PD in FDG and all pCITs, but midbrain URs were not significantly different between the PSP and PD groups in all pCITs. Correlations between each pCIT and FDG images are summarized in Figure 3. Good correlation was evident in all representative regions, especially in superior frontal cortex and cerebellum, in all pCITs. SPM Analysis Figure 4 shows the difference of regional uptake on pCITand FDG images in SPM t-maps of MSA-P, MSA-C, and PSP groups compared with PD patients. Patients with MSA-P showed a decrease in regional uptake in the posterior putamen and cerebellar cortex on all pCITand FDG images, with more prominent decrease of putamen evident in FDG images. In the MSA-C group, all pCIT and FDG images showed similarly decreased regional uptake in the cerebellar cortex. Patients with PSP showed significantly decreased regional uptake in the medial frontal cortex in all pCIT and FDG images, with more prominent decrease in FDG and pCIT-10m than in pCIT-5m or 7m. Regarding the midbrain, FDG images showed significant difference but not all pCITs. Comparison of Image Quality Among pCITs In visual analysis, pCIT-5m and pCIT-7m looked noisier than pCIT-10m (P < 0.001 and P = 0.006, respectively). There was no significant difference in image noise between pCIT-5m and pCIT-7m. Table 2 summarizes the results of quantitative analysis of image quality. Signal-to-noise ratio significantly increased with acquisition time. Putamen contrast increased, and cerebellum contrast decreased with acquisition time. DISCUSSION We investigated the ability to separate APD from PD in pCITs like FDG images with regard to regional uptake pattern and compared the image quality among pCITs. Relative regional uptakes of pCITs were similar to FDG images with significant difference between PD and APDs, especially in MSA-P and MSA-C patients. Regarding PSP, pCIT-10m showed a more prominent decrease in frontal lobe in SPM analysis with higher concordant rate in visual analysis than in images acquired shorter. pCIT-10m looked less noisy than shorter images in visual analysis and displayed the highest SNR. Good detection sensitivity for differential diagnosis of parkinsonism has been reported using dual-phase pCIT with early-phase 10-minute static images acquired 5 minutes after tracer injection.23 There was a lack of consideration for the time frame of early-phase images. Peak 18F-FP-CIT uptake in dopamine-poor regions, such as the cerebral cortex or cerebellum, is around the first 10 minutes after injection.17?20 This likely affected DAT binding after the time point. Therefore, we obtained the first 10-minute dynamic image for information closer to the real perfusion. However, 18F-FP-CIT traces DAT binding, not perfusion, so DAT binding around 10 minutes may still be subject to influence. However, a short acquisition time produces images that are too poor in quality to give proper information. We compared images acquired at first 5, 7, and 10 minutes after administration of FP-CIT to optimize the acquisition time. Because regional CBF in general is coupled to cerebral metabolism in normal individuals23 as well as those with PD,33 we compared these pCITs to images of FDG, a glucose analog. The use of FDG is well established and is widely used for differential diagnosis of parkinsonism.11?13 Yet, some regions show differences between perfusion and metabolism in brain, with hyperperfusion evident in the putamen,34 midbrain34 and cerebellum,34?36 and hypoperfusion evident in the superior frontal lobe.34,35 It is concordant to our result (Fig. 2), suggesting that pCIT images reflect perfusion well. These results have some clinical implications for visual interpretation. Because of lower FDG uptake in the cerebellum compared to the cerebral cortex, even in the PD (normal) group, mildly decreased metabolism of cerebellum is often difficult to find. But, in pCITs normal cerebellar uptake is approximately equal to the uptake of the cerebral cortex, so decreased cerebellar uptake is readily apparent compared to cerebral uptake. Indeed, a scattergram of cerebellar URs of all MSA-C subjects was less than 1 all pCIT images, but not in FDG images. Further research is needed to clarify whether this affects diagnostic efficiency. Despite these differences between perfusion and metabolism, our results show that all of the early time frame images correlated well to the FDG in regional uptake pattern (R > 0.5, all), especially in dopamine-poor brain regions including the frontal cortex and cerebellum, which displayed better correlation with time. In dopaminerich brain regions, such as the putamen and midbrain,worse correlation with time was evident. This is probably due to the different kinetics between dopamine-poor and ?rich regions. Concerning the differentiation of parkinsonism, which is considered more important, all pCITs showed significantly decreased uptake of putamen in MSA-P or cerebellum in MSA-C compared to PD, as in FDG images. But, themidbrain in PSP failed to show significant differences in all pCITs, while differences were seen in FDG images. This is probably due to a partial volume effect involving the small volume of themidbrain. However, the number of PSP patientswas too small to draw any conclusions. In SPM analysis, almost the same results were obtained, but more prominent decreased uptake of the frontal lobe in the PSP group was shown in pCIT-10 m than in earlier images. Visual interpretation also showed superior diagnostic concordance rate for differentiatingMSA-P orMSA-C than PSP from PD, and the interpreters differentiated PSP better in pCIT-10 m than in earlier images, probably due to more prominent decreased uptake of frontal lobe showing in SPM analysis. As for image quality, due to longest acquisition time of pCIT-10 m among pCITs, it is reasonable that SNR was highest. This would have produced better results in SPMand visual analysis of pCIT-10mimages.Meanwhile, the GM/WMcontrast in superior frontal VOI decreased with time, contrary to that in the putamen, probably due to the different kinetics of 18F-FP-CIT between dopamine-poor and dopamine-rich regions.However, the difference of contrast was too small (<0.1) to influence visual interpretation. Several methodological and clinical limitations of the present study deserve mention. First, there was no pathologic confirmation of the clinical diagnosis and clinical follow-up after PETwas short (<1 year). Therefore, misdiagnosis could have occurred because of the lack of postmortem verification.37 We did not investigate the diagnostic values of pCIT images but rather compared image findings with FDG images, and all diagnoses were based on strict diagnostic criteria. Therefore, a longer period of follow-up and comparison of diagnostic accuracy between FDG and pCIT images are needed. Second, considering the current subcentimeter spatial resolution of a PET scanner and the sizes of small brain regions like the midbrain, partial-volume effects cannot be excluded. Given that nonlinear partial-volume effects lead to an underestimation of the concentration of radioactivity in small lesions,38 quantification of signals in the midbrain likely would be particularly affected. Indeed, all pCITs failed to show significantly decreased uptake of midbrain in the PSP group compared with the PD group. Third, template-based VOI analysis might further reduce resolution during the normalization of individual PET images. Spatially normalized PET images of some patients showed misregistration with predefined VOI templates. This problem might be intrinsic to template-based analysis39 for patients with severe cerebral or cerebellar atrophy40 and advanced stages of parkinsonian disorders.41 Fourth, we used global count normalization for quantitative analysis. This is a widely used method for quantitation in neurodegenerative diseases.33,42 However, cortical uptake in PD would be decreased, notably in the advanced stage, which can bias the results, especially in small anatomical structures.43 There is no appropriate reference region for every parkinsonian group, decreased uptake of occipital lobe in advanced PD and cerebellum in MSA-C. The concordant results of visual, quantitative and SPM analyses suggest that this bias was not significant in this study. Fifth, this study is not a controlled prospective study, so there are some problems in composition of the disease group. The number of PSP patients was too few to warrant a definitive conclusion. In addition, the disease duration of the PD group was longer than those of APD groups. In addition, many of the patients with PD (15/23) included in this study underwent 18F-FP-CIT and 18F-FDG PET forworkup before deep-brain stimulation, in contrast with patients with APD, for diagnostic workup. Deep brain stimulation is usually considered in therapeutically resistant PD.44 It was likely relatively longer or more severe form of PD in this study showing significant longer disease duration in PD patients than in APD patients. In addition, putaminal DAT binding in PD was significantly lower than MSA-P (data not shown). Future studies including various severities of PD and APD will be needed. The final limitation was the lack of a normal group. We identified differences between PD and each APD in pCITs, similar to the FDG images but could not differentiate between normal and PD. For more accurate interpretation of pCIT, more study about the normal group is needed. Despite these limitations, this study is valuable. It is the first study to show that early time frame of 18F-FP-CIT reflects perfusion well, using a direct comparison with FDG. These early time frame pCITs may potentially provide FDG-like information in addition to the DAT binding in the same study. This would reduce radiation exposure, and medical and time costs for parkinsonian patients. CONCLUSION 18F-FP-CIT PET differentiated APD from PD as well as FDG, especially in MSA. Regional cerebral uptake patterns of all pCITs correlated well with FDG PET images, and there was little difference with regard to relative uptake among pCITs. However, pCIT-10m showed more prominent decreased uptake in the frontal lobe in SPManalysis with higher SNR than earlier images, allowed better discriminating of PSP. Therefore, pCITs acquired early (first 10minutes) could be useful for the differential diagnosis of APD by providing complementary FDG-like information to the DAT binding on late-phase FP-CIT images. 본 발명의 실시예와 관련하여 설명된 방법 또는 알고리즘의 단계들은 하드웨어로 직접 구현되거나, 하드웨어에 의해 실행되는 소프트웨어 모듈로 구현되거나, 또는 이들의 결합에 의해 구현될 수 있다. 소프트웨어 모듈은 RAM(Random Access Memory), ROM(Read Only Memory), EPROM(Erasable Programmable ROM), EEPROM(Electrically Erasable Programmable ROM), 플래시 메모리(Flash Memory), 하드 디스크, 착탈형 디스크, CD-ROM, 또는 본 발명이 속하는 기술 분야에서 잘 알려진 임의의 형태의 컴퓨터 판독가능 기록매체에 상주할 수도 있다."}
{"patent_id": "10-2017-0144930", "section": "발명의_설명", "subsection": "발명을실시하기위한구체적인내용", "paragraph": 3, "content": "이상, 첨부된 도면을 참조로 하여 본 발명의 실시예를 설명하였지만, 본 발명이 속하는 기술분야의 통상의 기술 자는 본 발명이 그 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 그러므로, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며, 제한적이 아닌 것으로 이해해야만 한다. 도면 도면1 도면2"}
{"patent_id": "10-2017-0144930", "section": "도면", "subsection": "도면설명", "item": 1, "content": "도 1 및 도 2는 PET를 이용한 질환분석 방법을 설명하기 위한 도면이다."}
